Lantheus (NASDAQ:LNTH) Posts Earnings Results, Beats Estimates By $0.50 EPS

Lantheus (NASDAQ:LNTH) released its quarterly earnings results on Thursday. The medical equipment provider reported $1.67 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.50, FiscalAI reports. The business had revenue of $406.79 million for the quarter, compared to analysts’ expectations of $367.03 million. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The firm’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.59 earnings per share. Lantheus updated its FY 2026 guidance to 5.000-5.250 EPS.

Here are the key takeaways from Lantheus’ conference call:

• Lantheus has refocused on PET radiodiagnostics, completing acquisitions of Neuraceq and OCTEVY and divesting its legacy SPECT business, which management says diversifies near‑term revenue and leaves the company with the broadest radiodiagnostic pipeline among peers.
• Management expects multiple near‑term regulatory milestones — PDUFA for the new PSMA F‑18 formulation (Mar 6), OCTEVY (Mar 29), MK‑6240 (Aug 13) and a mid‑year Hatch‑Waxman ruling for PNT2003 — and plans a regional PMF rollout of the new PSMA formulation in Q4 2026, with material commercial impact beginning in 2027.
• Reported Q4 revenue was $406.8M and FY‑2025 revenue $1.5416B; guidance for 2026 is $1.4–$1.45B in revenue and EPS of $5.00–$5.25, while management also expects PYLARIFY net revenue to decline ~8%–10% in 2026 as modest price erosion offsets volume.
• Cash generation weakened — Q4 operating cash flow fell to $90.2M (from $157.7M) and free cash flow to $81.4M — while the company incurred ~$21.7M of acquisition/integration/divestiture costs and other charges; it did repurchase $100M of shares and ended the quarter with ~$359.1M in cash.

Lantheus Price Performance

Shares of LNTH traded down $0.29 during midday trading on Thursday, reaching $75.43. The stock had a trading volume of 2,191,128 shares, compared to its average volume of 762,766. Lantheus has a 12-month low of $47.25 and a 12-month high of $111.29. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51. The company’s 50-day moving average is $67.97 and its 200 day moving average is $60.01. The company has a market capitalization of $5.00 billion, a price-to-earnings ratio of 31.69 and a beta of -0.08.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on LNTH shares. Citizens Jmp upped their price objective on Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a research note on Tuesday. Citigroup reissued an “outperform” rating on shares of Lantheus in a report on Tuesday. Weiss Ratings raised Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. William Blair raised shares of Lantheus from a “market perform” rating to an “outperform” rating in a report on Thursday. Finally, Mizuho boosted their price target on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, December 17th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $78.83.

Key Headlines Impacting Lantheus

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 beat — Lantheus reported $1.67 EPS vs. $1.17 expected and revenue of $406.8M vs. $367.0M expected, with improved margins and ROE, supporting near‑term earnings power. MarketBeat: Q4 results
• Positive Sentiment: Analyst upgrade — William Blair upgraded LNTH to “Outperform,” a vote of confidence that can support buying interest. Street Insider: William Blair upgrade
• Positive Sentiment: Price target increase — Citizens Jmp raised its price target to $78, which can provide a modest valuation floor for the shares. American Banking News: PT raise
• Neutral Sentiment: Earnings call / disclosure materials posted — Full earnings call transcript, slide deck and press release are available for investors to dig into segment details and management commentary. Seeking Alpha: Earnings call transcript
• Negative Sentiment: Cautious FY‑2026 guidance — Management set EPS guidance of $5.00–$5.25 (consensus ~5.16) and revenue guidance $1.4B–$1.5B (consensus ~$1.5B). The midpoint and lower end of the revenue range are slightly light versus Street expectations, creating near‑term uncertainty on growth trajectory. GlobeNewswire: Q4 results & guidance
• Negative Sentiment: Intraday selling on mixed setup — despite the beat and upgrades, investors pulled back on the guidance and booked profits after a big run from the stock in the prior year. WTOP: Earnings snapshot

Institutional Investors Weigh In On Lantheus

Several institutional investors have recently bought and sold shares of LNTH. EverSource Wealth Advisors LLC increased its stake in shares of Lantheus by 190.2% in the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock worth $87,000 after buying an additional 698 shares during the period. First Trust Advisors LP lifted its position in Lantheus by 37.4% during the second quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider’s stock valued at $5,714,000 after buying an additional 19,008 shares during the period. Baird Financial Group Inc. boosted its stake in Lantheus by 22.6% during the second quarter. Baird Financial Group Inc. now owns 2,715 shares of the medical equipment provider’s stock worth $222,000 after acquiring an additional 500 shares in the last quarter. Daiwa Securities Group Inc. increased its position in Lantheus by 88.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,396 shares of the medical equipment provider’s stock valued at $278,000 after buying an additional 1,591 shares in the last quarter. Finally, Osterweis Capital Management Inc. purchased a new position in shares of Lantheus in the 2nd quarter worth about $36,000. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.